• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CXCL9是一种在结直肠癌中具有双重作用的生物标志物，与线粒体自噬相关，并受ALKBH5调节。

CXCL9 is a dual‑role biomarker in colorectal cancer linked to mitophagy and modulated by ALKBH5.

作者信息

Hu Geng, Shen Shijun, Zhu Mingchao

机构信息

Department of Laboratory, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, P.R. China.

Department of Hepatobiliary and Pancreatic Minimally Invasive Surgery, Lincang People's Hospital, Lincang, Yunnan 677099, P.R. China.

出版信息

Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13553. Epub 2025 May 9.

DOI:10.3892/mmr.2025.13553
PMID:40341964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12076282/
Abstract

Colorectal cancer (CRC), the third most prevalent cancer globally, shows a diminished 5‑year survival rate compared with patients at early stages of the disease, underscoring the urgency for early diagnostic biomarker identification. The C‑X‑C motif chemokine ligand (CXCL) family plays a significant role in immune modulation and cancer progression. the present study constructed a prognostic model for CXCL family in CRC and conducted an in‑depth investigation of the hub gene CXCL9 within the model. CXCL9 is highly expressed in CRC while high expression levels of CXCL9 in patients with CRC often indicates an improved prognosis. Through Gene Ontology, Kyoto Encyclopedia of Genes and Genomes and gene set enrichment analysis enrichment analysis, it was discovered that CXCL9 is not only associated with immune modulation but also closely related to pathways that affect the occurrence and development of cancer. CXCL9 is closely related to mitophagy and blocks autophagy flow by altering the expression of autophagy‑related genes. Additionally, it was found that CXCL9 is a downstream gene modified by ALKBH5 and can partially restore the tumor‑suppressive effects induced by the knockdown of ALKBH5. These studies indicated that CXCL9 is a prognostic marker in CRC and plays a dual role in cancer progression: It activates immune responses on one hand and promotes the malignant characteristics of cancer on the other hand.

摘要

结直肠癌（CRC）是全球第三大常见癌症，与疾病早期患者相比，其5年生存率较低，这凸显了识别早期诊断生物标志物的紧迫性。C-X-C基序趋化因子配体（CXCL）家族在免疫调节和癌症进展中发挥着重要作用。本研究构建了CRC中CXCL家族的预后模型，并对模型中的核心基因CXCL9进行了深入研究。CXCL9在CRC中高表达，而CRC患者中CXCL9的高表达水平通常表明预后改善。通过基因本体论、京都基因与基因组百科全书和基因集富集分析发现，CXCL9不仅与免疫调节有关，还与影响癌症发生和发展的途径密切相关。CXCL9与线粒体自噬密切相关，并通过改变自噬相关基因的表达来阻断自噬流。此外，发现CXCL9是由ALKBH5修饰的下游基因，并且可以部分恢复ALKBH5敲低诱导的肿瘤抑制作用。这些研究表明，CXCL9是CRC中的一种预后标志物，并且在癌症进展中发挥双重作用：一方面激活免疫反应，另一方面促进癌症的恶性特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/aed7f05a9f39/mmr-32-01-13553-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/05f5cfd52d68/mmr-32-01-13553-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/0bb121a8dc86/mmr-32-01-13553-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/3d66a32b604c/mmr-32-01-13553-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/6186f6a47657/mmr-32-01-13553-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/eac160c2df09/mmr-32-01-13553-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/4a9dd791b627/mmr-32-01-13553-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/d9909316deca/mmr-32-01-13553-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/aed7f05a9f39/mmr-32-01-13553-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/05f5cfd52d68/mmr-32-01-13553-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/0bb121a8dc86/mmr-32-01-13553-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/3d66a32b604c/mmr-32-01-13553-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/6186f6a47657/mmr-32-01-13553-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/eac160c2df09/mmr-32-01-13553-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/4a9dd791b627/mmr-32-01-13553-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/d9909316deca/mmr-32-01-13553-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/278c/12076282/aed7f05a9f39/mmr-32-01-13553-g07.jpg

相似文献

1
CXCL9 is a dual‑role biomarker in colorectal cancer linked to mitophagy and modulated by ALKBH5.CXCL9是一种在结直肠癌中具有双重作用的生物标志物，与线粒体自噬相关，并受ALKBH5调节。
Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13553. Epub 2025 May 9.
2
The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients.趋化因子CXCL9的表达与结直肠癌患者较好的预后相关。
Biomed Pharmacother. 2016 Mar;78:8-13. doi: 10.1016/j.biopha.2015.12.021. Epub 2016 Jan 8.
3
Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer.结直肠癌中 CXC 趋化因子的表达及预后价值的综合分析。
Int Immunopharmacol. 2020 Dec;89(Pt B):107077. doi: 10.1016/j.intimp.2020.107077. Epub 2020 Oct 14.
4
High Expression Level of TRIP6 is Correlated with Poor Prognosis in Colorectal Cancer and Promotes Tumor Cell Proliferation and Migration.TRIP6高表达水平与结直肠癌预后不良相关，并促进肿瘤细胞增殖和迁移。
Biochem Genet. 2025 Feb;63(1):261-280. doi: 10.1007/s10528-024-10711-x. Epub 2024 Mar 2.
5
Prediction of the survival status and tumor microenvironment in colorectal cancer through genotyping analysis based on toll-like receptors.基于 Toll 样受体的基因分型分析预测结直肠癌的生存状态和肿瘤微环境。
Saudi J Gastroenterol. 2024 Jul 1;30(4):243-251. doi: 10.4103/sjg.sjg_424_23. Epub 2024 May 30.
6
CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.CX3CR1 在结直肠癌肿瘤微环境中作为一种保护性生物标志物。
Front Immunol. 2022 Jan 24;12:758040. doi: 10.3389/fimmu.2021.758040. eCollection 2021.
7
IL-17 inhibits CXCL9/10-mediated recruitment of CD8 cytotoxic T cells and regulatory T cells to colorectal tumors.IL-17 抑制 CXCL9/10 介导的 CD8 细胞毒性 T 细胞和调节性 T 细胞向结直肠肿瘤的募集。
J Immunother Cancer. 2019 Nov 27;7(1):324. doi: 10.1186/s40425-019-0757-z.
8
ITGB5 is a prognostic factor in colorectal cancer and promotes cancer progression and metastasis through the Wnt signaling pathway.整合素β5（ITGB5）是结直肠癌的一个预后因素，并通过Wnt信号通路促进癌症进展和转移。
Sci Rep. 2025 Mar 18;15(1):9225. doi: 10.1038/s41598-025-93081-7.
9
A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.与结直肠癌预后和免疫微环境相关的自噬相关基因特征。
Sci Rep. 2022 Nov 4;12(1):18688. doi: 10.1038/s41598-022-23463-8.
10
Unraveling molecular and clinical aspects of ALKBH5 as dual role in colorectal cancer.揭示 ALKBH5 在结直肠癌中双重作用的分子和临床方面。
J Pharm Pharmacol. 2024 Nov 4;76(11):1393-1403. doi: 10.1093/jpp/rgae108.

本文引用的文献

1
SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes.SPRED2 是肝细胞癌细胞和正常肝细胞自噬的新型调节因子。
Int J Mol Sci. 2024 Jun 6;25(11):6269. doi: 10.3390/ijms25116269.
2
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.局部晚期错配修复缺陷型结直肠癌的新辅助免疫治疗。
N Engl J Med. 2024 Jun 6;390(21):1949-1958. doi: 10.1056/NEJMoa2400634.
3
N6-Methyladenosine Demethylase ALKBH5 Promotes Pyroptosis by Modulating PTBP1 mRNA Stability in LPS-Induced Myocardial Dysfunction.
N6-甲基腺苷去甲基化酶ALKBH5通过调节PTBP1 mRNA稳定性促进脂多糖诱导的心肌功能障碍中的细胞焦亡。
Acta Cardiol Sin. 2024 May;40(3):312-321. doi: 10.6515/ACS.202405_40(3).20240127A.
4
Tuberculous pleural effusion-induced Arg-1 macrophage polarization contributes to lung cancer progression via autophagy signaling.结核性胸腔积液诱导的 Arg-1 巨噬细胞极化通过自噬信号促进肺癌进展。
Respir Res. 2024 May 8;25(1):198. doi: 10.1186/s12931-024-02829-8.
5
Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors.整合公共数据集以发现和验证实体瘤中与生存相关的基因
Innovation (Camb). 2024 Apr 9;5(3):100625. doi: 10.1016/j.xinn.2024.100625. eCollection 2024 May 6.
6
Lanosterol synthase deficiency promotes tumor progression by orchestrating PDL1-dependent tumor immunosuppressive microenvironment.羊毛甾醇合酶缺乏通过协调PDL1依赖性肿瘤免疫抑制微环境促进肿瘤进展。
MedComm (2020). 2024 Apr 10;5(4):e528. doi: 10.1002/mco2.528. eCollection 2024 Apr.
7
The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.CXCL11 及其受体在癌症中的作用：有前景但具有挑战性的临床靶点。
Cancer Control. 2024 Jan-Dec;31:10732748241241162. doi: 10.1177/10732748241241162.
8
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.CXCL9/10 工程化树突状细胞促进 T 细胞激活，并增强肺癌的免疫检查点阻断。
Cell Rep Med. 2024 Apr 16;5(4):101479. doi: 10.1016/j.xcrm.2024.101479. Epub 2024 Mar 21.
9
M6A modification regulates tumor suppressor DIRAS1 expression in cervical cancer cells.M6A 修饰调控宫颈癌细胞中肿瘤抑制因子 DIRAS1 的表达。
Cancer Biol Ther. 2024 Dec 31;25(1):2306674. doi: 10.1080/15384047.2024.2306674. Epub 2024 Feb 19.
10
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer.转移性结直肠癌的靶向治疗和免疫治疗进展。
Cells. 2024 Jan 28;13(3):245. doi: 10.3390/cells13030245.